COVID-19: New Corona Remedy; List by Japanese Pharmaceutical Manufacturers
COVID-19:
In Japan, five therapeutic candidates are currently in clinical development.
Some treatments have begun in international clinical trials or in large, company-led trials.
As early as this month, some preliminary data will be revealed.
As of early April, the following drugs are undergoing observational research and clinical trials for new corona in Japan.
FUJIFILM / Toyama Chemical: Avigan: Favipiravir
Fabipiravir, a new type of influenza drug (product name: Avigan),
Since it has the effect of preventing the growth of influenza virus, its use as a therapeutic drug has been expected from an early stage.
In mid-March, Chinese trials reported good results.
A phase III clinical trial in Japan by Fujifilm Toyama Chemical has started.
It will be held until about the end of June for about 100 patients.
Teijin Pharma: Orbesco: Ciclesonide
5 products, including asthma drug “ciclesonide” (product name: Orvesco).
National Institute of Infectious Disease confirms positive results for ciclesonide
Observational and clinical studies targeting patients with effects on the lungs are planned in Japan.
Nichiiko: “Fusan”: Nafamostat
The University of Tokyo announces the results of Nafamostat, a treatment for acute pancreatitis (including Nichi-Iko’s Fusan).
Combination trials are being planned at the National Center for Global Health and Medicine.
Gilead Sciences, Inc .: Laemdesivir
Remdecivir, which was developed as a treatment for Ebola hemorrhagic fever,
Japan also participated in the international phase III trial launched by NIH at the end of February.
Approximately 440 patients from Japan and abroad have been included in critically ill patients with pulmonary inflammation, and preliminary data will be available in April and May.
Chugai: Actemra
Promising is Actemra, an antibody drug created by Chugai.
It was originally a treatment for rheumatoid arthritis and other drugs, but was also recommended in China as a new type of corona treatment.
Roche, Switzerland, has begun clinical trials abroad, and Chugai is considering whether to participate in this trial.
hemical Daily